Johnson & Johnson's Caplyta meets primary endpoint in bipolar I mania trial

September 21, 2026 8:00 AM

Johnson & Johnson (NYSE: JNJ) announced that its drug Caplyta (lumateperone) met the primary endpoint in a pivotal Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found